24 Advanced Solid Tumors Clinical Trials in Huntersville, NC (2026)

Q: How do I join a clinical trial in Huntersville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Huntersville research site will contact you.

Recruiting Advanced Solid Tumors Studies in Huntersville

NCT00571389Recruiting

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this ...

Huntersville, NC1,500 participantsBioCytics, Inc.

View Study Details

NCT07749586Recruiting

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which mean...

Huntersville, NCPHASE1499 participantsArvinas Inc.

View Study Details

NCT06892379Recruiting

A Study of HS-20110 in Participants With Advanced Solid Tumors

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors...

Huntersville, NCPHASE1475 participantsHansoh BioMedical R&D Company

View Study Details

NCT06545331Recruiting

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with lo...

Huntersville, NCPHASE1396 participantsExelixis

View Study Details

NCT06554795Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors...

Huntersville, NCPHASE1360 participantsDualityBio Inc.

View Study Details

NCT04900818Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors....

Huntersville, NCPHASE1330 participantsI-Mab Biopharma US Limited

View Study Details

NCT04977453Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or lo...

Huntersville, NCPHASE1317 participantsGI Innovation, Inc.

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

Huntersville, NCPHASE1248 participantsBioNTech SE

View Study Details

NCT04777994Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor recep...

Huntersville, NCPHASE1248 participantsCalico Life Sciences LLC

View Study Details

NCT06480552Recruiting

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2...

Huntersville, NCPHASE1240 participantsTeva Branded Pharmaceutical Products R&D LLC

View Study Details

NCT07109726Recruiting

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors ha...

Huntersville, NCPHASE1205 participantsTerremoto Biosciences Inc.

View Study Details

NCT06265688Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult pa...

Huntersville, NCPHASE1160 participantsCytomX Therapeutics

View Study Details

NCT05267626Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...

Huntersville, NCPHASE1159 participantsAulos Bioscience, Inc.

View Study Details

NCT07123103Recruiting

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion co...

Huntersville, NCPHASE1150 participantsExelixis

View Study Details

NCT07030257Recruiting

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: ...

Huntersville, NCPHASE1150 participantsTasca Therapeutics

View Study Details

NCT07360314Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metas...

Huntersville, NCPHASE1138 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT07807956Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics o...

Huntersville, NCPHASE1130 participantsAbbVie

View Study Details

NCT06014658Recruiting

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biolog...

Huntersville, NCPHASE1130 participantsMBrace Therapeutics

View Study Details

NCT06667141Recruiting

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic sol...

Huntersville, NCPHASE1100 participantsAcrivon Therapeutics

View Study Details

NCT05055609Recruiting

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated...

Huntersville, NCPHASE194 participantsTrethera

View Study Details

NCT05892718Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what ...

Huntersville, NCPHASE180 participantsFBD Biologics Limited

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Huntersville, NCPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT07161414Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety...

Huntersville, NCPHASE140 participantsAstraZeneca

View Study Details

NCT05431270Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in ...

Huntersville, NCPHASE140 participantsPhanes Therapeutics

View Study Details

About Advanced Solid Tumors Clinical Trials in Huntersville

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 24 advanced solid tumors clinical trials recruiting participants in Huntersville, NC. These studies are seeking a combined 6,254 participants. Research is being sponsored by BioCytics, Inc., Arvinas Inc., Hansoh BioMedical R&D Company and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Huntersville — FAQ

Are there advanced solid tumors clinical trials in Huntersville?

Yes, there are 24 advanced solid tumors clinical trials currently recruiting in Huntersville, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Huntersville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Huntersville research site will contact you about next steps.

Are clinical trials in Huntersville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Huntersville studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 24 active trials in Huntersville are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated October 20, 2026 from ClinicalTrials.gov